Giovanna Catania
Overview
Explore the profile of Giovanna Catania including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bellanca R, Pinna A, Catania G, Belcastro E, Angi M, DAmico Ricci G
Ocul Immunol Inflamm
. 2022 Feb;
31(2):402-406.
PMID: 35113757
Purpose: To describe a case of ocular inflammation associated with dabrafenib and trametinib chemotherapy for cutaneous melanoma by using a multimodal image approach. Materials And Methods: We report on a...
2.
Fabi A, Ciccarese M, Scagnoli S, Russillo M, Schettini F, Buono G, et al.
Oncology
. 2021 Dec;
PMID: 34875670
Background: To date, a consensus has not yet been reached about the therapy sequence after disease progression (PD) on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer (MBC). Objectives:...
3.
Cognetti F, Masetti R, Fabi A, Bianchi G, Santini D, Rognone A, et al.
NPJ Breast Cancer
. 2021 May;
7(1):47.
PMID: 33953182
Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to...
4.
Di Cosimo S, Tagliaferri B, Generali D, Giudici F, Agustoni F, Bernardo A, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33809465
Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT)...
5.
Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi C, Griguolo G, et al.
Clin Cancer Res
. 2021 Mar;
27(12):3443-3455.
PMID: 33785482
Purpose: The mTOR complex C1 (mTORC1) inhibitor everolimus in combination with the aromatase inhibitor exemestane is an effective treatment for patients with hormone receptor-positive (HR), HER2-negative (HER2), advanced breast cancer...
6.
Fabi A, Ferretti G, Malaguti P, Gasparro S, Nistico C, Arpino G, et al.
Future Oncol
. 2020 Jun;
16(22):1629-1637.
PMID: 32501121
To investigate the toxicity of nab-paclitaxel (wNP)/nonpegylated liposome-encapsulated doxorubicin (wNPLD) combination in HER2-negative metastatic breast cancer (MBC) patients as first-line treatment. Phase I, single-arm study in metastatic breast cancer patients...
7.
Rossi V, Berchialla P, Giannarelli D, Nistico C, Ferretti G, Gasparro S, et al.
Cancers (Basel)
. 2019 Nov;
11(11).
PMID: 31717791
Methods: A network meta-analysis (NMA) using the Bayesian hierarchical arm-based model, which provides the estimates for various effect sizes, were computed. Results: First-line treatment options in HR+/HER2- MBC, including CDK...
8.
Fabi A, Catania G
Recenti Prog Med
. 2019 Aug;
110(7):347-355.
PMID: 31379370
LHRH analogues (LHRHa) are used in the treatment of breast cancer that occurs in young women. Amenorrhoea induced by chemotherapy correlates with a reduced risk of recurrence disease. In premenopausal...
9.
Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, et al.
Breast
. 2018 Aug;
41:137-143.
PMID: 30092500
Background: We reported the results of an Italian large retrospective analysis that evaluated the effectiveness and safety of T-DM1 in 'field-practice' breast cancer patients. We performed a sub-analysis to investigate...
10.
Catania G, Malaguti P, Gasparro S, Cognetti F, Vidiri A, Fabi A
Oncology
. 2018 Jul;
94 Suppl 1:29-33.
PMID: 30041177
Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis. Case Report: We report the case of a...